Altimmune Presents New Data On The Effect Of Pemvidutide On Inflammatory Lipids In Subjects With Metabolic Dysfunction-Associated Steatotic Liver Disease At The Liver Meeting 2024
Altimmune Presents New Data On The Effect Of Pemvidutide On Inflammatory Lipids In Subjects With Metabolic Dysfunction-Associated Steatotic Liver Disease At The Liver Meeting 2024
GAITHERSBURG, Md., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today presented new data from its 12-week Phase 1b trial of pemvidutide in metabolic dysfunction-associated steatotic liver disease (MASLD) at The Liver Meeting of the American Association for the Study of Liver Diseases. The data showed reductions in multiple classes of inflammatory lipid species associated with adverse cardiovascular outcomes. Pemvidutide is a balanced GLP-1/glucagon dual receptor agonist in development for the treatment of MASH and obesity.Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids
皮安維杜肽每週皮下注射劑量導致心臟炎症、肝炎炎症和動脈粥樣硬化脂質的顯著降低。
Findings support the potential benefit of pemvidutide on co-morbidities of metabolic dysfunction-associated steatohepatitis (MASH), including atherosclerosis, heart disease and metabolic syndrome
研究結果支持皮安維杜肽對代謝功能失調相關脂肪肝（MASH）併發症，包括動脈硬化、心臟病和代謝綜合徵的潛在益處。
Pemvidutide is currently being evaluated in IMPACT, the Phase 2b trial in subjects with MASH; data readout expected in Q2 2025
皮安維杜肽當前正在IMPACt評估中，這是針對MASH患者的第20億期試驗；數據公佈預計在2025年第二季度。
GAITHERSBURG, Md., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today presented new data from its 12-week Phase 1b trial of pemvidutide in metabolic dysfunction-associated steatotic liver disease (MASLD) at The Liver Meeting of the American Association for the Study of Liver Diseases. The data showed reductions in multiple classes of inflammatory lipid species associated with adverse cardiovascular outcomes. Pemvidutide is a balanced GLP-1/glucagon dual receptor agonist in development for the treatment of MASH and obesity.
馬里蘭蓋瑟斯堡，2024年11月15日（環球新聞社）—Altimmune, Inc.（納斯達克：ALT），一家臨床階段生物製藥公司，今天在美國肝病研究協會肝病學討論會上展示了其關於皮安維杜肽在代謝功能失調相關肥胖性脂肪肝（MASLD）12周第10億期試驗的新數據。數據顯示，與不良心血管結果相關的多種炎症脂質種類減少。皮安維杜肽是一種用於治療MASH和肥胖症的平衡GLP-1/胰高血糖素受體激動劑。
The new data were derived from an analysis of plasma samples from subjects who completed a randomized placebo-controlled Phase 1b trial of pemvidutide in subjects with overweight or obesity and MASLD. In the Phase 1b clinical trial, 94 subjects with obesity or overweight and liver fat content (LFC) ≥10% were dosed 1:1:1:1 to pemvidutide (1.2mg, 1.8mg and 2.4mg) or placebo administered once-weekly subcutaneously for 12 weeks. In this study, pemvidutide reduced LFC relative to baseline by up to 68.5% and decreased total cholesterol and triglycerides by up to 12.2% and 44.6%, respectively, after 12 weeks of treatment.
新數據來源於對完成了皮安維杜肽在超重或肥胖以及MASLD患者中隨機安慰劑對照第10億期試驗的受試者血漿樣本的分析。在第10億期臨床試驗中，94名超重或肥胖以及肝脂含量（LFC）≥10%的受試者被1:1:1:1地分配到每週一次皮下注射的皮安維杜肽（1.2毫克、1.8毫克和2.4毫克）或安慰劑治療12周。在這項研究中，與基線相比，皮安維杜肽可將LFC減少高達68.5%，並在治療12周後將總膽固醇和三酰甘油分別降低高達12.2%和44.6%。
The goal of the study was to characterize changes in the lipid profile of patients before and after treatment with pemvidutide. In this study of 50 subjects, treatment with pemvidutide was shown to reduce plasma concentrations of atherogenic lipoproteins and lipotoxic lipid classes associated with MASH and implicated in cardiovascular and atherosclerotic disease. In particular, a rapid and significant reduction in small atherogenic LDL particles was observed in the 1.8 mg and 2.4 mg dose groups compared to placebo.
該研究的目標是描述接受皮安維杜肽治療前後患者的脂質畫像變化。在這項涉及50名受試者的研究中，皮安維杜肽治療顯示可以降低與MASH相關並涉及心血管和動脈粥樣硬化疾病的致病脂質類別的血漿濃度。特別地，與安慰劑相比，1.8毫克和2.4毫克劑量組中小型致病性LDL顆粒迅速且顯著減少。
譯文內容由第三人軟體翻譯。
